Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals
with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of …

Objective To provide guidance to rheumatology providers on the management of adult
rheumatic disease in the context of the coronavirus disease 2019 (COVID‐19) pandemic …

Deciphering the molecular downstream consequences of severe acute respiratory
syndrome coronavirus (SARS-CoV)− 2 infection is important for a greater understanding of …

At the end of 2019, a novel flu‐like coronavirus named COVID‐19 (coronavirus disease
2019) was recognized by World Health Organization. No specific treatments exist for COVID …

COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Around 2· 5 million deaths and more than 110 million COVID-19 cases have been reported
globally. Although it initially appeared that HIV infection was not a risk factor for COVID-19 or …

Since the outbreak of COVID-19 many studies have been published showing possible
therapies, here the author discusses the end of stage disease related drugs, like …

A hyperinflammatory response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …

A subset of patients with severe COVID-19 develop profound inflammation and multi-organ
dysfunction consistent with a “Cytokine Storm Syndrome”(CSS). In this review we compare …